Merilee Raines - Jun 14, 2023 Form 4 Insider Report for OCULAR THERAPEUTIX, INC (OCUL)

Role
Director
Signature
/s/Donald Notman, Attorney-in-Fact for Merilee Raines
Stock symbol
OCUL
Transactions as of
Jun 14, 2023
Transactions value $
$0
Form type
4
Date filed
6/16/2023, 07:05 PM
Previous filing
May 30, 2023
Next filing
Jul 31, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OCUL Common Stock Award $0 +12K +134.33% $0.00 20.9K Jun 14, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OCUL Stock Option (Right to Buy) Award $0 +36K $0.00 36K Jun 14, 2023 Common Stock 36K $5.31 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On June 14, 2023, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.
F2 Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.